ENDO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENDO, and what generic alternatives to ENDO drugs are available?
ENDO has two hundred and thirty-one approved drugs.
There are forty-four US patents protecting ENDO drugs. There is one tentative approval on ENDO drugs.
There are two hundred and seventy-seven patent family members on ENDO drugs in forty-two countries and three hundred and fifty-three supplementary protection certificates in seventeen countries.
Summary for ENDO
| International Patents: | 277 |
| US Patents: | 44 |
| Tradenames: | 182 |
| Ingredients: | 158 |
| NDAs: | 231 |
| Patent Litigation for ENDO: | See patent lawsuits for ENDO |
| PTAB Cases with ENDO as petitioner: | See PTAB cases with ENDO as petitioner |
| PTAB Cases with ENDO as patent owner: | See PTAB cases with ENDO as patent owner |
Drugs and US Patents for ENDO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-003 | Dec 9, 2011 | DISCN | Yes | No | 8,192,722 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Endo Operations | ADRENALIN | epinephrine | SOLUTION;INTRAVENOUS | 215875-002 | Apr 21, 2023 | RX | Yes | Yes | 11,083,698 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | DOXYCYCLINE HYCLATE | doxycycline hyclate | INJECTABLE;INJECTION | 216690-001 | Dec 7, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Endo Operations | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-003 | Apr 15, 2020 | RX | Yes | Yes | 9,919,026 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENDO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Operations | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-004 | Jun 22, 2006 | 7,276,250 | ⤷ Sign Up |
| Endo Operations | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-006 | Feb 29, 2008 | 7,276,250 | ⤷ Sign Up |
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-006 | Dec 9, 2011 | 8,329,216 | ⤷ Sign Up |
| Endo Operations | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021610-003 | Jun 22, 2006 | 7,276,250 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | Injection | 20 units/mL, 1 mL | ➤ Subscribe | 2018-03-23 |
| ➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-05-29 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2011-03-09 |
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
| ➤ Subscribe | Gel | 1% | ➤ Subscribe | 2008-08-21 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Injection | 1 mg/mL ampules | ➤ Subscribe | 2016-03-09 |
| ➤ Subscribe | Extended-release Tablets | 5 mg, 10 mg, 20 mg and 40 mg | ➤ Subscribe | 2007-11-23 |
| ➤ Subscribe | Extended-release Tablets | 30 mg | ➤ Subscribe | 2008-06-12 |
| ➤ Subscribe | Gel | 10 mg/actuation | ➤ Subscribe | 2012-08-14 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Injection | 250 mg/mL | ➤ Subscribe | 2014-06-11 |
International Patents for ENDO Drugs
Supplementary Protection Certificates for ENDO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1534313 | 15C0090 | France | ⤷ Sign Up | PRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728 |
| 1044189 | SPC/GB08/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928 |
| 0663916 | 14/2004 | Austria | ⤷ Sign Up | PRODUCT NAME: EVEROLIMUS (40-0-(2-HYDROXY)ETYHL RAPAMYCIN); NAT. REGISTRATION NO/DATE: 1-25271;1-25272; 1-25275,1-25276. 20040302; FIRST REGISTRATION: SE 18690;18691;18692; 18693;18694;18695. 20030718 |
| 0265685 | C980030 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
